Ipsen scores first-line nod for Onivyde combo in pancreatic cancer
2024-02-13
临床结果临床3期上市批准并购引进/卖出
The FDA on Tuesday approved a four-drug regimen featuring Ipsen’s Onivyde (irinotecan liposome injection) to treat first-line metastatic pancreatic adenocarcinoma. Known as NALIRIFOX, the treatment combines the topoisomerase inhibitor with fluorouracil, leucovorin and oxaliplatin.
Onivyde was previously cleared by the agency as part of a slightly different combination for metastatic pancreatic adenocarcinoma in patients who progressed following gemcitabine-based therapy.
The latest approval is welcome news for pancreatic cancer patients, who have few treatment options beyond chemotherapy. While Merck & Co.’s PD-1 inhibitor Keytruda (pembrolizumab) and its AstraZeneca-partnered PARP drug Lynparza (olaparib) are both approved for the disease, they’re limited to small, genetically defined populations. For more, see ViewPoints: Ipsen success provides epitaph for Merrimack.
NALIRIFOX’s green light was based on data from Phase III NAPOLI 3 trial, in which it bested standard care with nab-paclitaxel plus gemcitabine to improve survival for patients with metastatic pancreatic cancer.
NAPOLI 3 enrolled 770 patients who had not previously received chemotherapy. The Onivyde regimen achieved overall survival of 11.1 months, compared with 9.2 months for the comparator arm, meeting the primary endpoint. Patients who received NALIRIFOX also had a median progression-free survival of 7.4 months, versus 5.6 months for the chemotherapy-only cohort.
Ipsen acquired US rights to OnivydeOnivyde from Merrimack Pharmaceuticals in 2017; with the first-line approval now in hand, the latter stands to receive a $225-million milestone payment.
Servier is responsible for commercialisation of OnivydeOnivyde outside of the US, as well as outside of Taiwan, where PharmaEngine has rights.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。